GSK reports 'exceptional' result from respiratory drug trial
GSK
1,353.50p
16:40 14/11/24
-0.62%
-8.50p
Pharma giant GSK said its respiratory syncytial virus (RSV) vaccine was 82.6% effective, according to phase 3 trial data from a study of older adults.
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
RSV is a common contagious virus affecting the lungs and breathing passages. It is one of the major remaining infectious diseases for which there is currently no vaccine or specific treatment available for adults, GSK said.
Older adults are at high risk for severe disease due to age-related decline in immunity and underlying conditions.
"These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research," said GSK chief scientific officer Tony Wood.
Reporting by Frank Prenesti for Sharecast